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Objective: Variation in the major histocompatibility complex (MHC) on chromosome 6p21 is known to influence susceptibility
to multiple sclerosis with the strongest effect originating from the HLA-DRB1 gene in the class II region. The possibility that
other genes in the MHC independently influence susceptibility to multiple sclerosis has been suggested but remains uncon-
firmed.
Methods: Using a combination of microsatellite, single nucleotide polymorphism, and human leukocyte antigen (HLA) typing,
we screened the MHC in trio families looking for evidence of residual association above and beyond that attributable to the
established DRB1*1501 risk haplotype. We then refined this analysis by extending the genotyping of classical HLA loci into
independent cases and control subjects.
Results: Screening confirmed the presence of residual association and suggested that this was maximal in the region of the
HLA-C gene. Extending analysis of the classical loci confirmed that this residual association is partly due to allelic heterogeneity
at the HLA-DRB1 locus, but also reflects an independent effect from the HLA-C gene. Specifically, the HLA-C*05 allele, or a
variant in tight linkage disequilibrium with it, appears to exert a protective effect (p  3.3  10
5).
Interpretation: Variation in the HLA-C gene influences susceptibility to multiple sclerosis independently of any effect attrib-
utable to the nearby HLA-DRB1 gene.
Ann Neurol 2007;61:228–236
It is well established that the major histocompatibility
complex (MHC) on chromosome 6p21 contains at
least one gene that influences susceptibility to multi-
ple sclerosis.
1–6 Although this association was first
identified more than 30 years ago
1 through the study
of class I human leukocyte antigens (HLAs), it was
quickly realized that this signal was predominantly, if
not exclusively, the result of linkage disequilibrium
(LD) with class II HLA genes, and that these exert
the primary effect on susceptibility.
7,8 The complex
nature of the MHC, especially its high gene content,
extreme polymorphism, and extensive LD,
9 has con-
founded efforts to resolve the nature of the MHC as-
sociation in multiple sclerosis, although progress and
useful clarifications have been made, especially in re-
cent years.
In virtually every population studied, multiple scle-
rosis is found to be associated with the DRB1*1501
allele.
10 The only exceptions are those populations
where this allele has a low frequency, and analysis is
therefore underpowered; but even in these situations,
DRB1*1501 is generally overrepresented in cases.
11
The DRB1*1501 allele is carried on a particularly ex-
tensive haplotype,
12 the most common DR15 haplo-
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ants from flanking genes, even some located quite a
distance from DRB1, have sufficient LD with
DRB1*1501 that they invariably also show evidence for
association with the disease in any population where
association with DRB1*1501 can be demonstrat-
ed.
11,13–17 This extensive LD has made it difficult to
establish which of the variants making up this haplo-
type is primarily responsible for the association. The
distinction between DRB1*1501 and DQB1*0602 has
been particularly taxing because the LD between these
closely mapped genes is especially tight in those popu-
lations where the disease is frequent, that is, white Eu-
ropeans and their migrant descendants. However, re-
cent studies in the admixed African American
population indicate the supremacy of the DRB1*1501
allele.
18
In the presence of one susceptibility allele it is diffi-
cult to identify effects attributable to a second allele,
19
especially if the second allele exerts a more modest ef-
fect or has a low frequency, or both. However, by an-
alyzing populations where DR15 haplotypes are less
common, and by using large cohorts, it has been pos-
sible to demonstrate that the DRB1*0301 allele also
confers susceptibility to multiple sclerosis, thereby con-
firming allelic heterogeneity at the DRB1 locus.
4,6,18,20
Furthermore available evidence suggests that the sus-
ceptibility effects of the DRB1*1501 allele may be
modulated by other DRB1 alleles.
6,20
The relation between the MHC and multiple sclero-
sis is further complicated by the accumulating evidence
suggesting that MHC loci mapping outside DRB1 also
influence susceptibility to the disease.
11,13–16 Work in
animal models suggests that clustering of susceptibility
loci is a common phenomenon in complex disease,
21
and it therefore appears reasonable to expect that other
genes from the MHC region may influence suscepti-
bility to multiple sclerosis. The observation of positive
logarithm of odds scores in the MHC region in linkage
studies stratified for the effects of DRB1 supports the
existence of secondary loci,
22–24 although none of these
data reaches a level providing statistical confidence. In
considering these linkage data, it is important to re-
member that early linkage studies in multiple sclero-
sis
25–27 were significantly underpowered,
28 to the point
that they could not even convincingly demonstrate ev-
idence for linkage resulting from the effects of DRB1.
Confirmation of linkage in this region has been estab-
lished only in more recent studies involving many hun-
dreds of families.
23,24,29 Given the inherently limited
resolution of linkage-based studies,
28 the absence of
statistically significant linkage in the MHC region after
exclusion of primary effects attributable to DRB1 does
not exclude the presence of secondary loci. Several au-
thors have attempted to identify secondary loci using
more powerful association-based methods. Two groups
have typed dense microsatellite maps of the region and
both found evidence for a secondary locus maximal in
a region close to HLA-A: one group identifying the
marker D6S1683 just telomeric of HLA-A,
11 and the
second group implicating a region including HLA-A
extending from MOGCA to D6S265 marker.
14
Follow-up studies in Norway also found evidence im-
plicating the D6S265 marker.
16 In another smaller
study, a microsatellite marker close to HLA-C (marker
C1_3_2) also showed evidence for an independent ef-
fect.
15 In contrast, a systematic effort to screen the
MHC and flanking regions using single nucleotide
polymorphisms (SNPs) found no evidence for associa-
tion beyond that attributable to DRB1*1501, although
this study was limited by a high genotyping failure rate
(40%) and, more importantly, a distribution of mark-
ers leaving regions close to the classical loci essentially
unexplored.
17 In all of these studies, statistical power
has inevitably been reduced by the processes required
to filter out the primary effect attributable to DRB1
and the large correction required for multiple testing.
Unfortunately, none of the published studies has used
sufficient samples to compensate for these statistical
penalties, and thus none is able to provide unequivocal
evidence supporting any particular secondary locus.
Subjects and Methods
UK Trio Families and Sporadic Cases
The 480 trio families (an affected individual and both par-
ents) and 721 sporadic cases participating in our study were
recruited from across the United Kingdom. All subjects in-
volved in this study gave written informed consent and pro-
vided a venous blood sample from which DNA was extracted
and normalized. Comparing data from the five classical loci
in the trio family index cases (n  480) with those from the
sporadic cases (n  721) showed that there was no statisti-
cally significant difference between these two cohorts. The
clinical details for each set of cases are summarized in Table
1. All cases were diagnosed according to recognized crite-
ria.
30,31
UK Extension Analysis Control Cohorts
The fully anonymous control data used in the extension
analysis were derived from three sources: local organ donors,
national organ donor records held by UK Transplant (UKT),
and the 1958 birth cohort. Ethical permission for using these
data was obtained from the appropriate respective research
ethics committees. Data from all five classical loci (HLA-A,
-B, -C, -DRB1, and -DQB1) were available for the donor
and UKT cohorts, whereas these were available for only three
loci in the 1958 birth cohort (HLA-B, -DRB1, and -DQB1).
Only white individuals from these cohorts with complete
data were included: 408 for the donor cohort, 2,201 for the
UKT cohort, and 1,051 for the 1958 birth cohort (total
3660 individuals). There was no evidence for any statistically
significant difference among these three cohorts in a pairwise
comparison of the classical loci. We also compared each of
the three control cohorts with the nontransmitted alleles
I.M.S.C.: MHC Susceptibility Locus for MS 229from the 480 trio families. Again, there was no evidence for
any statistically significant difference.
US Trio Families
All cases from the 450 US trio families were diagnosed ac-
cording to the McDonald criteria.
31 All individuals involved
in this study gave written informed consent using documents
approved by the institutional review board and provided a
venous blood sample from which DNA was extracted and
normalized. The clinical details for the 450 index cases from
the trio families are summarized in Table 1.
Screening Single Nucleotide Polymorphisms
The recently completed resequencing of the MHC region
from consanguineous homozygous cell lines carrying specific
disease-associated haplotypes provided a comprehensive and
detailed description of these haplotypes.
32,33 By comparing
the sequence from the PGF line, which carries the multiple
sclerosis–associated DR15 haplotype (HLA-A3-B7-Cw7-
DR15), with the other completed haplotypes, COX (HLA-
A1-B8-Cw7-DR3) and QBL (A26-B18-Cw5-DR3), we were
able to identify 241 coding variants (outside the hypervari-
able regions). These variants distinguish the multiple sclero-
sis–associated haplotype from alternatives and are therefore
especially promising candidate susceptibility variants. To in-
crease the coverage provided by this set of markers, we also
developed assays for SNPs already identified as tagging com-
mon haplotypes in the MHC region
34 and supplemented
this list with variants from the class III region. Working as-
says were established for a total of 110 SNPs, including 5
from the extended class I region, 1 from the extended class II
region, and 104 from the classical MHC. Seventy SNPs were
genotyped using a Sequenom MassArray MALDI-TOF plat-
form,
35 whereas the remaining 40 were genotyped using
TaqMan allelic discrimination assays on an ABI7900HT
genotyping platform (Applied Biosystems, Foster City,
CA).
36 The primer sequences used and basic performance
characteristics for each marker are included in Supplemen-
tary Table S1.
Screening Microsatellites
To generate a screening set of microsatellites, we first iden-
tified an exhaustive list of such markers (n  248) lying
within the extended MHC using published
37–41 and publicly
available resources: National Center for Biotechnology Infor-
mation (NCBI) UniSTS (Build 34.3; http://www.ncbi.nlm-
.nih.gov/entrez/query.fcgi?dbunists), GDB Human Ge-
nome Database (http://www.gdb.org), and Ensembl (Build
22.34d.1; http://www.ensembl.org/index.html). From En-
sembl BLAST (http://www.ensembl.org/Multi/blastview) and
electronic polymerase chain reaction (ePCR) analysis
42
(NCBI; http://www.ncbi.nlm.nih.gov/sutils/e-pcr), with em-
phasis on markers previously suggested to be of relevance in
multiple sclerosis,
11,14,15 we then selected markers from this
list to produce an informative map with a density of approx-
imately 1 marker per 50 to 100kb across the classical MHC
region (29.8–33.2Mb
9). The 69 markers selected were then
typed in a trial set of 122 trio families. Seventeen markers
were found to be monomorphic and two assays failed; we
used the remaining 50 markers in our study. These 50 in-
cluded 8 from the extended class I region, 4 from the ex-
tended class II region, and 38 from the classical MHC itself.
Each microsatellite was amplified by PCR using TrueAllele
PCR Premix and the manufacturer’s standard conditions
(Applied Biosystems). The PCR products were genotyped on
a 3700 Genetic Analyzer (Applied Biosystems) using GE-
NESCAN version 3.5 (Applied Biosystems) and GENO-
TYPER version 3.7 (Applied Biosystems) software. The
primer sequences used and basic performance characteristics
for each marker are included in Supplementary Table S1.
Human Leukocyte Antigen Typing
In the screening of trio families, four-digit (medium-
resolution) typing of HLA-DRB1 and HLA-DQB1 was per-
formed in all the UK trios and 60% of the US trios.
20,43 In
the remaining US trios, lower resolution typing was per-
formed as described later. For the analysis of all 930 trio
families together, the resolution was down grouped to the
low-resolution level. The class I loci in the UK trio families
and all the HLA typing performed in the sporadic cases was
low-resolution typing based on PCR with sequence-specific
primers, as developed by Olerup and Zetterquist
44 and pre-
viously used by us.
45 Alleles were assigned using World
Health Organization nomenclature. The HLA-DRB1*15 al-
leles were subtyped into HLA-DRB1*1501, 1502, or 1503.
The primer sequences and combinations for each PCR reac-
tion are given in Supplementary Table S2.
LD between DRB1 and the other classical loci was con-
firmed in both the trio family and extension data sets; esti-
mates for Global D’ and Cramer’s V (measures of LD be-
Table 1. Patient Demographics
Demographics
US Trio Index
(n  450)
UK Trio Index
(n  480)
UK Sporadic
(n  721)
Sex (M:F) 1:3.2 1:3.2 1:2.5
Mean age (yr) 39 38 48
Mean age at onset (yr) 29 25 33
Mean EDSS 4.0 4.4 4.6
Mean duration (yr) 11 13 15
The slightly younger age and greater proportion of female individuals seen in cases from the trio families in each population reflects the
requirement for both parents to be alive and willing to take part. This necessarily means that these patients tend to be younger, and because
the disease has a younger age at onset in female individuals, also results in an increased proportion of women.
EDSS  Extended Disability Status Scale.
230 Annals of Neurology Vol 61 No 3 March 2007tween multiallelic loci) are summarized in Table 2. As
expected, the extent of LD is inversely correlated with the
distance from DRB1. It should be noted that although the
extent of LD between class I loci and DRB1 is modest, this
level of LD is sufficient to produce an association signal at
class I loci secondary to DRB1 effects. Indeed, this is pre-
cisely how the association between the MHC and multiple
sclerosis was first recognized. Allele counts and frequencies
for the five classic loci in the screening and extension data
sets are provided in Supplementary Table S3.
Statistical Analysis
Transmission disequilibrium testing (TDT) of data from trio
families was performed using the TDTPHASE program, part
of the UNPHASED suite.
46 Before analysis, Mendelian er-
rors were zeroed out using the PEDCHECK program,
47 and
basic performance characteristics were established using the
PEDSTATS program.
48 In the extension study, case–control
association testing was performed using the COCAPHASE
program, also part of the UNPHASED suite.
46 In all tests,
we used the EM option and grouped rare alleles (haplotypes)
with expected counts of less than 10 in both case (transmit-
ted) and control subjects (nontransmitted). This cutoff was
chosen to ensure that we did not include alleles where the
available data were insufficient to provide any power. In con-
ditional analysis, we used the main-effects test. Measures of
LD were also calculated using the relevant UNPHASED
program. For multiallelic markers, UNPHASED calculates
Global D’ and Cramer’s V as measures of the overall extent
of LD. Nontransmitted alleles in the trio families were iden-
tified using the MERLIN program,
49 ignoring alleles where
phase was uncertain.
Results
To refine the relation between the MHC and multiple
sclerosis, we first screened the region by genotyping
110 SNPs and two class II HLA loci (HLA-DRB1 and
HLA-DQB1) in a cohort of 930 trio families (an af-
fected individual and their parents): 480 from the
United Kingdom and 450 from the United States. In
addition, we also typed 50 microsatellite markers and 3
class I HLA loci (HLA-A, -B, and -C) in the same 480
UK trios. As expected, multiple markers showed highly
significant evidence for association (see Supplementary
Table S4 for individual results). To eliminate the con-
founding effects of LD with the DRB1*1501 allele, we
excluded all families where either parent carried a
DRB1*1501 allele and reanalyzed the data from the re-
maining 318 families (146 from the United Kingdom
and 172 from the United States). The results generated
in this subgroup analysis are also listed in Supplemen-
tary Table S4. After stringent Bonferroni correction for
the number of markers tested (n  165), we found
that two markers continued to show statistically signif-
icant evidence for association: HLA-C (pcorrected 
0.04) and rs3132552 (pcorrected  0.006), a synony-
mous coding polymorphism in the corneodesmosin
gene. Because rs3132552 lies just 151kb telomeric of
HLA-C, it was not surprising to find substantial LD
between these loci in the UK trios (Global D’  0.61).
Testing rs3132552 in the DRB1*1501-negative trios
from the United States and United Kingdom indepen-
dently demonstrated that the marker shows association
in both populations (puncorrected  0.001 in the US
cohort; puncorrected  0.009 in the UK cohort). These
data demonstrate that there is significant residual asso-
ciation within the MHC region above and beyond that
attributable to the well-established association with
DRB1*1501. However, the power available in this
modest DRB1*1501-negative subgroup, together with
the extensive LD between the various MHC loci,
makes it impossible to establish with any confidence
which locus is primarily responsible for the observed
effect.
Consequently, to further refine the nature of the sec-
ondary MHC association identified in our screening
experiment, we typed the five classical HLA loci
(HLA-A, -B, -C, -DRB1, and -DQB1) in an additional
721 sporadic UK multiple sclerosis patients and estab-
Table 2. Multiallelic Measures of Linkage Disequilibrium between DRB1 and the Other Classical Loci
Locus Cases Control Subjects Transmitted Nontransmitted
Global D’
HLA-A 0.24 0.24 0.29 0.32
HLA-C 0.42 0.44 0.51 0.53
HLA-B 0.49 0.47 0.56 0.56
HLA-
DQB1
0.91 0.91 0.97 0.95
Cramer’s V
HLA-A 0.18 0.19 0.27 0.28
HLA-C 0.26 0.28 0.31 0.36
HLA-B 0.34 0.36 0.31 0.33
HLA-
DQB1
0.78 0.79 0.82 0.82
The higher resolution of HLA-DRB1 and HLA-DQB1 typing together with the greater degree of phase information explains why the estimates
for linkage disequilibrium are generally higher in this cohort than in the case–control analysis.
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viduals (see Subjects and Methods). Given that the US
trio families provided independent evidence implicat-
ing the HLA-C region, we analyzed these new data
from additional UK samples together with those from
the 480 UK index cases used in the first screening ex-
periment in the form of an extension analysis as op-
posed to a replication study.
50 Results from the first-
pass unstratified analysis of all 1,201 cases and 3,660
control subjects are shown in Table 3. Association with
DRB1 is overwhelmingly the most significant, with the
majority of this effect attributable to the DRB1*1501
allele (puncorrected  4.5  10
88). After excluding all
individuals carrying DRB1*1501, analysis of the re-
maining data continues to show highly significant evi-
dence for association with the most significant effect
still appearing to come from the DRB1 locus (see Ta-
ble 3). As expected, the majority of the residual DRB1
effect is attributable to the DRB1*03 allele (puncor-
rected  6.3  10
5). Therefore, we next excluded all
individuals carrying DRB1*03 alleles. Analysis of the
remaining data shows that significant evidence for as-
sociation is still evident but only at HLA-C and DRB1
(see Table 3). At DRB1, the only allele showing signif-
icant evidence for association is the DRB1*0103 allele
(puncorrected  1.8  10
5). Even though this allele is
relatively uncommon, we also excluded all individuals
carrying the DRB1*0103 allele. In this final stratified
analysis, statistically significant association is only ap-
parent at the HLA-C locus (see Table 3). Analysis of
HLA-C after conditioning on DRB1 has no important
effect on the evidence for association at this locus,
whereas conditioning on HLA-C confirms that none of
the four other loci exerts any residual main effects.
19,51
Inspection of the individual HLA-C alleles in the ex-
tension analysis shows that the HLA-C*05 allele is the
most significantly associated, being underrepresented in
cases (Table 4). Following a replication approach, in
which the original 480 index cases from the trio fam-
ilies are excluded, has little effect on the interpretation
of the results. The results from this replication ap-
proach are shown in the lower half of Table 3 for com-
parison. Our analysis indicates that three DRB1 alleles
(*1501, *03, and *0103) and one HLA-C allele (*05)
exert independent effects on susceptibility to multiple
sclerosis. To determine the risk associated with each
DRB1 susceptibility allele in haplotypes with and with-
out HLA-C*05, we reanalyzed the full data set three
times, first excluding all individuals carrying DRB1*03
or *0103, next excluding all individuals carrying
DRB1*1501 or *0103, and then finally after excluding
all individuals carrying DRB1*1501 or *03. Table 5
shows the relative risk associated with the various hap-
lotypic combinations of DRB1 and HLA-C alleles, as
Table 4. Individual HLA-Cw Allele Associations in Final
Subgroup of Data (in Which All Individuals Carrying
DRB1*1*15, *03, and *0103 alleles have been excluded; see
Table 3)
Allele
Cases, N
(%)
Control Subjects,
N (%) p
01 12 (2) 116 (5) 0.0061
02 34 (7) 133 (6) 0.38
03 76 (15) 403 (17) 0.22
04 67 (13) 252 (10) 0.12
05 37 (7) 320 (13) 3.3  10
5
06 71 (14) 278 (12) 0.19
07 110 (21) 470 (20) 0.41
08 32 (6) 113 (5) 0.18
12 18 (3) 75 (3) 0.69
14 6 (1) 21 (1) 0.56
15 24 (5) 49 (2) 0.0017
16 29 (6) 153 (6) 0.49
17 3 (1) 18 (1) 0.66
Table 3. Association of Classical Human Leukocyte Antigen Loci in the Case–Control Data Sets
Cohort Subgroups HLA-A HLA-C HLA-B HLA-DRB1 HLA-DQB1
Cases,
N
Control
Subjects,
N
Power,
%
a
Extension Analysis
Full 3.3  10
7 1.4  10
16
4.3  10
28 9.1  10
94 1.2  10
21 1,201 3,660 99.9
DRB1*15 excluded 3.4  10
4 3.2  10
5 5.3  10
6 5.2  10
7 3.1  10
4 481 2,635 95.2
DRB1*15 and *03 excluded 0.042 2.3  10
5 0.017 2.9  10
4 0.016 297 1,802 75.8
DRB1*15,* 03, and *0103 excluded 0.053 5.9  10
5 0.014 0.18 0.0075 264 1,724 69.5
Replication analysis
Full 1.1  10
4 1.2  10
10
7.9  10
13 6.7  10
53 4.2  10
14 1,201 3,660 99.6
DRB1*15 excluded 5.4  10
3 1.5  10
3 6.3  10
4 9.7  10
4 9.6  10
4 481 2,635 79.8
DRB1*15 and *03 excluded 0.21 2.6  10
4 0.010 0.16 0.012 297 1,802 50.2
DRB1*15,* 03, and *0103 excluded 0.36 1.2  10
3 0.017 0.61 8.2  10
3 264 1,724 44.9
As each of the 5 markers has been tested 4 times in each approach, a Bonferroni correction factor of no more than 20 is required. Applying
this to the nominal p values included in the table indicates that only those in bold are significant after this conservative correction for multiple
testing.
aThis column indicates the power of each analysis to identify a common allele (frequency 10%) conferring a risk with an odds ratio of 1.6
under a multiplicative model at a level of significance sufficient to survive Bonferroni correction (nominal p  0.0025).
57
232 Annals of Neurology Vol 61 No 3 March 2007compared with haplotypes carrying no associated allele
at either locus. The relative risk associated with haplo-
types carrying HLA-C*05 without DRB1 risk alleles is
consistent across the three analyses and is significantly
less than 1 in each case, confirming the protective na-
ture of this allele. The data suggest that the risk asso-
ciated with the DRB1*1501 allele is reduced but not
abolished by the presence of an HLA-C*05 allele on
the same haplotype. Unfortunately, the frequency of
the other combined haplotypes (DRB1*03 with HLA-
C*05 and DRB1*0103 with HLA-C*05) was too low
to provide sufficient statistical power to make a judg-
ment about whether the HLA-C*05 allele alters the risk
associated with the secondary DRB1 risk alleles.
Discussion
Using a combination of microsatellite, SNP, and HLA
typing in family-based and case–control cohorts from
two different populations, we have shown that HLA-C
exerts an independent effect on susceptibility to multi-
ple sclerosis above and beyond any effects attributable
to the nearby DRB1 gene. We found no support for
effects attributable to HLA-A or any of the microsatel-
lite loci previously suggested by other researchers, al-
though such effects cannot be excluded at this
time.
11,13,14,16 It remains possible that the observed as-
sociation with HLA-C is secondary to LD with a
nearby but as yet untyped variant. The absence of any
residual main effects at DQB1, HLA-B, and HLA-A
make it unlikely that the observed association results
from these loci despite their strong LD with HLA-C.
As with all genetic analyses of complex diseases, our
study has a number of limitations that need to be con-
sidered when evaluating its conclusions.
Adequate correction for multiple testing is particu-
larly important in studies that involve systematic
screening and stratification because the number of tests
performed is generally large.
52 However, calculating an
appropriate correction factor can be difficult when
there is LD between markers or when subsets (strata)
of data are analyzed in addition to total data sets. In
these situations, tests are partially correlated rather than
fully independent, and simply counting the number of
tests performed provides an excessively conservative
correction factor. Application of such a crude Bonfer-
roni correction
53 runs the risk for inflating the type II
error rate unless the sample size used is sufficient to
compensate for this conservatism. However, inaccurate
attempts to assess the degree of interdependence be-
tween tests might underestimate the correction re-
quired, thereby resulting in a type I error. Because
these plague the genetic analysis of multiple sclerosis,
we elected to apply the conservative Bonferroni correc-
tions at each stage. It might be argued that even this
approach is insufficient and that we should account for
all of the tests performed across the whole study and
not just those used at each stage. The evidence for as-
sociation we identified concerning HLA-C would re-
main significant even if such a project-wide correction
factor (approximately 300) were to be applied.
Association testing can be confounded by population
stratification and other phenomena that lead to inade-
quate matching of cases and control subjects. Our use
of trio families and transmission disequilibrium testing
Table 5. Haplotype Analysis of HLA-C and HLA-DRB1 in Subsets of the Case–Control (Extension) Cohort Showing the Relative
Risk with 95% Confidence Intervals for Each Haplotype
HLA-C HLA-DRB1
Cases, N
(%)
Control Subjects,
N (%) RR CI
Analysis 1 (excluding all individuals carrying DRB1*03 or *0103)
*R
a *X
a 900.3 (54.7) 2,589.0 (70.3) 1.00 —
*05 *X 75.7 (4.6) 395.7 (10.7) 0.55 0.40–0.76
*R *1501 634.7 (38.6) 652.7 (17.7) 2.80 2.42–3.23
*05 *1501 35.3 (2.1) 46.3 (1.3) 2.19 1.18–4.10
Analysis 2 (excluding all individuals carrying DRB1*1501 or *0103)
*R
a *Y
a 611.1 (70.1) 2,521.0 (70.8) 1.00 —
*05 *Y 50.9 (5.8) 396.5 (11.1) 0.53 0.37–0.75
*R *03 182.9 (21.0) 579.5 (16.3) 1.30 1.08–1.57
*05 *03 27.2 (3.1) 64.5 (1.8) 1.74 0.96–3.15
Analysis 3 (excluding all individuals carrying DRB1*1501 or *03)
*R
a *Z
a 514.0 (87.7) 2,121.0 (84.7) 1.00 —
*05 *Z 39.0 (6.7) 332.0 (13.3) 0.49 0.34–0.69
*R *0103 33.0 (5.6) 51.0 (2.0) 2.96 1.63–4.37
*05 *0103 0( 0.0) 0( 0.0) — —
a*R indicates any HLA-C allele except *05,* X any DRB1 allele except *1501,* Y any DRB1 allele except *03, and *Z any DRB1 allele except
*0103.
RR  relative risk; CI  confidence interval.
I.M.S.C.: MHC Susceptibility Locus for MS 233protects against these confounders in the screening
phase. However, the extension phase experiments used
case–control analysis; therefore, results emerging from
these efforts could have been confounded by such er-
rors. The classical loci are highly polymorphic and pro-
vide a powerful means to test for stratification. The
absence of any difference between the three UK con-
trol cohorts or the two sets of UK cases is therefore
extremely reassuring in this respect. Perhaps even more
reassuring is the absence of any difference between the
unrelated UK control cohorts and nontransmitted al-
leles from the UK trio families, suggesting that our
cases are drawn from the same genetic background as
the control subjects and making it unlikely that hidden
population stratification accounts for our observations.
However, replication of the findings in independent
cohorts will be necessary to fully exclude this possibil-
ity.
Efforts to further replicate our findings will require
considerable resources because exclusion of individuals
carrying DRB1 susceptibility alleles means that only
47% of control subjects and 22% of cases will ulti-
mately be informative for the study of HLA-C. Large
initial cohorts would need to be selected to provide re-
alistic power. The absence of any statistically significant
difference in an underpowered study should not be
misinterpreted as evidence against this effect. Just as it
proved difficult to establish that DRB1*1501 is respon-
sible for the primary effect in this region, it may prove
even more difficult to refine this secondary effect in
detail. It remains possible that the observed association
is secondary to LD with a nearby but as yet untyped
variant. The absence of any residual main effects at
DQB1, HLA-B, and HLA-A make it unlikely that the
observed association results from these loci despite
their strong LD with HLA-C.
If HLA-C is, in fact, the locus primarily responsible
for our observations, this would implicate novel path-
ways in disease pathogenesis, in particular, the innate
immune system. HLA-C molecules, loaded with
nonamer peptides, act as ligands for the killer cell
immunoglobulin-like receptors (KIRs). KIR receptors
contain two or three immunoglobulin-like domains
and a short (KIR2DS, KIR3DS) or long (KIR2DL,
KIR3DL) cytoplasmic tail, corresponding to an activat-
ing or inhibitory action on the natural killer cells and
T-cell subsets on which they are expressed. Whereas
the ligands for activating KIRs remain elusive, and may
have relatively weak binding affinities, those for the in-
hibitory KIRs are well defined. The subset of HLA-C
alleles with Ser at position 77 and Asn at position 80
(C1 group) bind to the KIR2DL2 and KIR2DL3 recep-
tors, whereas those with Asn at position 77 and Lys at
position 80 (C2 group) bind to the KIR2DL1 receptor.
HLA-C peptide binding specificity may further influ-
ence interaction with KIRs.
54 No evidence for associa-
tion was seen in our data after grouping HLA-C alleles
according to this functional categorization, suggesting
that the protective effect seen for HLA-C*05 is specific
to this allele, and not a consequence of its group func-
tion. Alternately, as the effect appears to be allele rather
than functional group specific, it may indicate that sus-
ceptibility to multiple sclerosis is conferred by an as-
pect of HLA-C function that is independent of its in-
teraction with KIR.
The established association of HLA-C*06 with sus-
ceptibility to psoriasis provides a clear precedent for the
involvement of HLA-C in complex inflammatory dis-
ease. In a Sardinian study of psoriasis, HLA-C*05 was
found to be significantly underrepresented (protective)
in patients, although it was not established whether
this effect is independent of or secondary to the over-
representation of HLA-C*06 and/or haplotypes con-
taining risk alleles at the nearby corneodesmosin
(CDSN) gene,
55 in which our most highly associated
SNP, rs3132552, is found. Recently, the presence of
the activating KIR2DS1 and KIR2DS2 genes was re-
ported to be a novel risk factor for psoriasis and an
interaction between HLA-C and KIR observed with the
overall combination of activating and inhibitory geno-
types influencing susceptibility.
56 Association of com-
binations between HLA class I and KIR genes has also
been reported for a range of other infectious and au-
toimmune diseases.
54 This provides a strong rationale
for investigating the KIR gene cluster as a candidate
susceptibility locus in multiple sclerosis subsequent to
our finding of association with HLA-C. The fact that
the KIR gene cluster lies on chromosome 19 where
modest evidence of linkage was observed in the recent
high-density screen for linkage in multiple sclerosis
24
lends further support. In concordance with these re-
sults, this chromosome 19 linkage signal only declares
itself in an ordered subset analysis based on those fam-
ilies not showing linkage at MHC, essentially those
where the effects of DRB1*1501 have been excluded.
24
In conclusion, we show that the class I gene HLA-C,
or a locus in tight LD with it, confers additional effects
on susceptibility to multiple sclerosis, substantially add-
ing to our understanding of the MHC region in this
disease and offering a clear roadmap to further experi-
ments that will refine these observations in larger data
sets.
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